Fulcrum Therapeutics (FULC) Amortizatization of Intangibles (2020 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Amortizatization of Intangibles of $811000.0 for Q2 2026, down 25.25% year-over-year from $1.1 million in Q2 2025, and up 5.74% quarter-over-quarter from $767000.0 in Q1 2026.
Powered by 
Analysis
Fulcrum Therapeutics (FULC) Amortizatization of Intangibles (2020 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Amortizatization of Intangibles for 7 consecutive years, with $811000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Amortizatization of Intangibles fell 25.25% year-over-year to $811000.0; the TTM figure through Jun 2026 stood at $2.5 million (down 37.59% YoY), while the FY2025 annual figure was $3.0 million, down 32.76% from the prior year.
- Amortizatization of Intangibles climbed to $811000.0 in Q2 2026 per FULC's latest filing, from $767000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.7 million in Q2 2023 and bottomed at -$353000.0 in Q1 2022.
- Historically, Amortizatization of Intangibles has averaged $820111.1 across 5 years, with a median of $922000.0 in 2024.
- Annual changes were most pronounced in 2022 — Amortizatization of Intangibles tumbled 377.03% — and 2023, when it jumped 1515.18%.
- Fulcrum Therapeutics' Amortizatization of Intangibles stood at $601000.0 in 2022, then jumped by 120.97% to $1.3 million in 2023, then fell by 28.84% to $945000.0 in 2024, then tumbled by 59.47% to $383000.0 in 2025, then surged by 111.75% to $811000.0 in 2026.
- Business Quant data shows FULC's Amortizatization of Intangibles at $811000.0 in Q2 2026, $767000.0 in Q1 2026, and $383000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Fulcrum Therapeutics | 293.24 Mn | 293.24 Mn | - | 811,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 811,000.00 |
| Mar 31, 2026 | 767,000.00 |
| Dec 31, 2025 | 383,000.00 |
| Sep 30, 2025 | 586,000.00 |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | 899,000.00 |
| Dec 31, 2024 | 945,000.00 |
| Sep 30, 2024 | 1.15 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.16 Mn |
| Dec 31, 2023 | 1.33 Mn |
| Sep 30, 2023 | 1.59 Mn |
| Jun 30, 2023 | 1.71 Mn |
| Mar 31, 2023 | 1.37 Mn |
| Dec 31, 2022 | 601,000.00 |
| Sep 30, 2022 | -112,000.00 |
| Jun 30, 2022 | -288,000.00 |
| Mar 31, 2022 | -353,000.00 |
| Dec 31, 2021 | -386,000.00 |
| Sep 30, 2021 | -92,000.00 |